Turing Pharmaceuticals, which ignited a firestorm by acquiring a 62-year-old drug and increasing its price fiftyfold overnight, said on Tuesday that it would lower the price somewhat by the end of the year and take steps to broaden financial support to patients.

But the company, in a meeting on Tuesday in Washington with some of its critics, did not say how much the price would be lowered. In an interview with an H.I.V. activist this week, however, Martin Shkreli, the former hedge fund manager who founded and runs Turing, said the reduction would be on the order of 10 percent, an amount not likely to mollify many people.

“Since acquiring Daraprim three months ago, our top priority has been to ensure that patients who need Daraprim have ready, affordable access to it,” the company said in a letter given to the groups it met with on Tuesday.

Sean Dickson, a member of one of the groups, said in an interview after the meeting that he welcomed the company’s intention to fix the problems caused by the price increase but said the group was dissatisfied with the lack of specifics. “We don’t have any concrete understanding of the revised price or changes to patient assistance programs,” said Mr. Dickson, who is manager for health care access at the National Alliance of State & Territorial AIDS Directors.